ImmunityBio (IBRX) Reports Q1 Loss, Tops Revenue Estimates

ImmunityBio (IBRX) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of$ 0.12. This compares to loss of $0.20 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -25%. A quarter ago, it was expected that this immunotherapy company would post a loss of$ 0.26 per share when it actually produced a loss of $0.15, delivering a surprise of 42.31%.Over the last four quarters, the company has ...